Diana Maria Trasca

Dr. Diana Maria Trasca


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Renata Maria VarutRenata Maria Varut
Renata Maria Varut
DDDop Dalia
Dop Dalia
KRKristina Radivojević
Kristina Radivojević
DTDiana Maria Trasca
Diana Maria Trasca
ASAlin George Stoica
Alin George Stoica
CSCristina Elena Singer
Cristina Elena Singer
Asthma represents a heterogeneous disorder characterized by a dynamic balance between pro-inflammatory and anti-inflammatory forces, with allergic sensitization contributing substantially to airway hyperresponsiveness and remodeling. Central to its pathogenesis are cytokines such as IL-4, IL-5, IL-13, IL-17, and IL-33, which drive recruitment of eosinophils, neutrophils, and other effector cells, thereby precipitating episodic exacerbations in response to viral and environmental triggers. Conventional biomarkers, including blood and sputum eosinophil counts, IgE levels, and fractional exhaled nitric oxide, facilitate phenotypic classification and guide the emerging biologic era. Monoclonal antibodies targeting IgE (omalizumab) and IL-5 (mepolizumab, benralizumab, reslizumab, depemokimab) have demonstrated the ability to reduce exacerbation frequency and improve lung function, with newer agents such as depemokimab offering extended dosing intervals. Itepekimab, an anti-IL-33 antibody, effectively engages its target and mitigates tissue eosinophilia, while CM310-stapokibart, tralokinumab, and lebrikizumab inhibit IL-4/IL-13 signaling with variable efficacy depending on patient biomarkers. Comparative analyses of these biologics, encompassing affinity, dosing regimens, and trial outcomes, underscore the imperative of personalized therapy to optimize disease control in severe asthma.

21 October 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
APAndreea Silvia Pirvu
Andreea Silvia Pirvu
Renata Maria VarutRenata Maria Varut
Renata Maria Varut
DTDiana Maria Trasca
Diana Maria Trasca
GSGeorge-Alin Stoica
George-Alin Stoica
KRKristina Radivojević
Kristina Radivojević
CPCristina Popescu
Cristina Popescu
Cyclodextrins (CDs) have traditionally been recognized as excipients that enhance solubility and stability of drugs. However, growing evidence shows that CDs themselves can act as active therapeutic agents. Their unique supramolecular properties enable them to interact with biological membranes, mobilize cholesterol, and modulate immune responses. This review highlights four therapeutic areas where CDs demonstrate particular promise. First, in gene and mRNA therapy, cationic CD derivatives form nanoparticles that protect nucleic acids, promote endosomal escape, and achieve targeted delivery. Second, in neurodegenerative disorders such as Niemann–Pick type C and Alzheimer’s disease, hydroxypropyl-β-CD facilitates cholesterol clearance and reduces pathological lipid accumulation. Third, in detoxification, the γ-CD derivative sugammadex exemplifies a clinically approved agent that encapsulates neuromuscular blockers to reverse anesthesia. Finally, CDs have emerged as safe vaccine adjuvants, inducing robust systemic and mucosal immunity with reduced IgE responses compared to alum. Together, these examples illustrate a paradigm shift: CDs are not only versatile excipients but also active molecules with direct therapeutic effects. Future translation will require careful optimization of safety, scalability, and regulatory compliance, but CDs are poised to contribute meaningfully to next-generation medicines.

10 October 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Renata Maria VarutRenata Maria Varut
Renata Maria Varut
DTDiana Maria Trasca
Diana Maria Trasca
GSGeorge-Alin Stoica
George-Alin Stoica
CSCarmen Sirbulet
Carmen Sirbulet
CACristian Arsenie
Cristian Arsenie
CPCristina Popescu
Cristina Popescu
Orthopedic implants have a critical role in modern medical practice, being useful in bone regeneration, joint arthroplasty, and healing fractures. The success of osseointegration depends on implant properties (composition, stability, geometry, biocompatibility) and host factors (local reactivity, comorbidities). Preclinical evaluation in animal models is essential before clinical application. In orthopedic implantology, the selection and real utility of a range of animals are important, with an emphasis placed on bone–implant interface, biomechanical function, and long-term integration. Smaller animals such as rabbits and rats have widespread use in early biocompatibility and osseointegration testing, but larger animals such as pigs, sheep, and canines have a larger physiological bone similarity and can, therefore, be utilized for bearing loads in testing. Considering the utility and disadvantages of certain species—including suitability for new biomaterials, coatings, and biomechanical function—this article discusses testing methodologies such as push-out/pull-out tests, histomorphometry, and micro-CT and their utility in testing the integration of implants and regeneration of bone. Conclusions confirm a multi-species model in use in preclinical testing for the development of implants and improvements in clinical success. Unlike previous reviews, this article emphasizes translational strategies, integrates ethical perspectives in model selection, and discusses the synergistic use of imaging modalities with biomechanical tests for comprehensive assessment.

4 December 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
DTDiana Maria Trasca
Diana Maria Trasca
IPIon Dorin Pluta
Ion Dorin Pluta
CSCarmen Sirbulet
Carmen Sirbulet
Renata Maria VarutRenata Maria Varut
Renata Maria Varut
CSCristina Elena Singer
Cristina Elena Singer
GSGeorge-Alin Stoica
George-Alin Stoica
Background/Objectives: This review evaluates the expanding contributions of artificial intelligence (AI) across biomedicine, focusing on cancer therapy and nanomedicine, cardiology and medical imaging, neurodegenerative disorders, and liver disease. Core AI concepts (machine learning, deep learning, artificial neural networks, model training/validation, and explainability) are introduced to frame application domains. Methods: A systematic search of major biomedical databases (2010–2025) identified English-language original studies on AI in these four areas; 203 articles meeting PRISMA 2020 criteria were included in a qualitative synthesis. Results: In oncology and nanomedicine, AI-driven methods expedite nanocarrier design, predict biodistribution and treatment response, and enable nanoparticle-enhanced monitoring. In cardiology, algorithms enhance ECG interpretation, coronary calcium scoring, automated image segmentation, and noninvasive FFR estimation. For neurological disease, multimodal AI models integrate imaging and biomarker data to improve early detection and patient stratification. In hepatology, AI supports digital histopathology, augments intraoperative robotics, and refines transplant wait-list prioritization. Common obstacles are highlighted, including data heterogeneity, lack of standardized acquisition protocols, model transparency, and the scarcity of prospective multicenter validation. Conclusions: AI is emerging as a practical enabler across these biomedical fields, but its safe and equitable use requires harmonized data, rigorous multicentre validation, and more transparent models to ensure clinical benefit while minimizing bias.

4 May 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MPMihaela Popescu
Mihaela Popescu
KRKristina Radivojević
Kristina Radivojević
DTDiana Maria Trasca
Diana Maria Trasca
Renata Maria VarutRenata Maria Varut
Renata Maria Varut
IEIrina Enache
Irina Enache
OAOsman Andrei
Osman Andrei
Diabetes mellitus (DM) is a chronic disease with a growing prevalence worldwide, leading to severe health complications. Current treatment relies on antidiabetic medications, which may have adverse effects, highlighting the need for alternative approaches. Natural compounds, such as phenolic compounds, have shown promise in glucose modulation. The Ericaceae family includes several plants with potential antidiabetic properties. This review examines the pathophysiology of diabetes, chemical composition, and specific Ericaceae species that have demonstrated antidiabetic effects. Studies indicate that Vaccinium species and other Ericaceae plants can lower blood glucose levels and improve insulin sensitivity through mechanisms such as enzyme inhibition. These findings suggest that Ericaceae plants may serve as complementary strategies for diabetes management.

11 July 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
DTDiana Maria Trasca
Diana Maria Trasca
DDDop Dalia
Dop Dalia
ASAlin George Stoica
Alin George Stoica
NANiculescu Stefan Adrian
Niculescu Stefan Adrian
NCNiculescu Elena Carmen
Niculescu Elena Carmen
CSCristina Elena Singer
Cristina Elena Singer
Diabetes mellitus is a chronic metabolic disease that has a significant impact on public health and is becoming more and more common worldwide. Although effective, conventional therapies are often limited by high cost, adverse effects, and issues with patient compliance. As a result, there is growing interest in complementary and alternative therapies. Medicinal plants have played an essential role in diabetes treatment, especially in regions such as Romania, where biodiversity is high and traditional knowledge is well preserved. The pathophysiology, risk factors, and worldwide burden of diabetes are examined in this review, with an emphasis on the traditional use of medicinal plants for glycemic control. A total of 47 plant species were identified based on ethnopharmacological records and recent biomedical research, including both native flora and widely cultivated species. The bioactive compounds identified, such as flavonoids, triterpenic saponins, polyphenols, and alkaloids, have hypoglycemic effects through diverse mechanisms, including β-cell regeneration, insulin-mimetic action, inhibition of α-glucosidase and α-amylase, and oxidative stress reduction. A systematic literature search was conducted, including in vitro, in vivo, and clinical studies relevant to antidiabetic activity. Among the species reviewed, Urtica dioica, Silybum marianum, and Momordica charantia exhibited the most promising antidiabetic activity based on both preclinical and clinical evidence. Despite promising preclinical results, clinical evidence remains limited, and variability in phytochemical content poses challenges to reproducibility. This review highlights the potential of Romanian medicinal flora as a source of adjunctive therapies in diabetes care and underscores the need for standardization and clinical validation.